ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Business/EarningsArticle

CVS Group FY 2026 revenue rises 5.9% as Australia expansion gains pace

The veterinary services group posted £712.8 million revenue, 6.9% EPS growth and a 1.63x EBITDA leverage ratio, while shares slipped 5% on the results.

PA
Priya Anand · Equities & Earnings Desk · 24 Sept 2026 · 09:43 · 2 min read
Share
CVS Group FY 2026 revenue rises 5.9% as Australia expansion gains pace

CVS Group plc reported a 5.9% increase in total revenue to £712.8 million for the year ended 30 June 2026, up from £673.2 million the prior year. Adjusted EBITDA grew 5.1% to £141.5 million, keeping the adjusted EBITDA margin at 19.9%, a marginal 0.1‑point dip. Adjusted earnings per share rose 6.9% to 85.6 pence.

Like‑for‑like revenue growth slowed to 2.1% against a 4‑8% target range, while free cash flow fell 4.2% to £69.2 million. Net bank borrowings increased by £68.2 million to £199.6 million, leaving leverage at 1.63 times adjusted EBITDA, comfortably below the 2.0‑times guardrail. The company achieved an operating cash conversion of 70.6%, just above its >70% goal.

Segment results showed the Veterinary Practices division generating £648.2 million in revenue (up 5.2%) and £138.7 million adjusted EBITDA (up 4.3%). The Laboratory division posted £35.0 million revenue, an 11.5% rise, and £11.3 million adjusted EBITDA, up 25.6%. Online retail contributed £51.0 million revenue (up 11.1%) and £1.4 million adjusted EBITDA, a 7.7% increase.

Australian operations expanded to 57‑61 sites, delivering £79.1 million revenue, a 51% jump from the previous year, and a 3.0% like‑for‑like increase. Annualised Australian revenue now approaches £100 million, reflecting more than £170 million of cumulative investment.

The Healthy Pet Club membership base stood at 508,000, generating £95.5 million in revenue, while the newly launched Healthy Pet Club Advanced attracted roughly 14,500 clients after its July 2026 debut. Subscription fees start at £21.99 per month for dogs, £20.99 for cats and £15.99 for rabbits.

Shareholder returns totalled £38.0 million, including £31.7 million of share buybacks. Capital expenditure for the year was £36.4 million, with acquisition spend of £45.4 million and £12.8 million recorded as exceptional costs related to a Competition and Markets Authority investigation.

The results prompted a 5.07% decline in CVS Group shares, which traded around 1,236 GBX after the announcement. Chief Executive Richard Fairman said the figures “demonstrate another year of growth and strategic progress.”

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT